Who are Nextstellis's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Orserdu, Cerianna, Osphena, Duavee, Duavee, Fablyn.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/estetrol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Nextstellis — Competitive Intelligence Brief

Nextstellis (ESTETROL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen. Area: Other.

marketed Estrogen Estrogen receptor Other Small molecule Live · refreshed every 30 min

Target snapshot

Nextstellis (ESTETROL) — Mayne Pharma. Nextstellis works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nextstellis TARGET	ESTETROL	Mayne Pharma	marketed	Estrogen	Estrogen receptor	2021-01-01
Orserdu	ELACESTRANT	Stemline Therap	marketed	Estrogen Receptor Antagonist [EPC]	Estrogen receptor	2023-01-01
Cerianna	FLUOROESTRADIOL F-18	GE HealthCare	marketed	Radioactive Diagnostic Agent [EPC]	Estrogen receptor	2020-01-01
Osphena	OSPEMIFENE	Duchesnay	marketed	Estrogen Agonist/Antagonist [EPC]	Estrogen receptor beta	2013-01-01
Duavee	conjugated-estrogens-bazedoxifene	Pfizer	marketed	Estrogen [EPC]	estrogen receptors α and β	2013-01-01
Duavee	BAZEDOXIFENE	Wyeth Pharms Pfizer	marketed	Estrogen [EPC]	estrogen receptors (ER) α and β	2013-01-01
Fablyn	LASOFOXIFENE	Dr. Friedrich Eberth Arzneimittel GmbH	marketed	lasofoxifene	Estrogen receptor	2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-03-10 — Duavee · 7683051 · US

Sponsor landscape (Estrogen class)

· 7 drugs in this class
Pfizer · 2 drugs in this class
Mayne Pharma · 1 drug in this class
Pfizer Inc. · 1 drug in this class
Ph Health · 1 drug in this class
Merck & Co. · 1 drug in this class
Apil · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nextstellis — Competitive Intelligence Brief. https://druglandscape.com/ci/estetrol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab